Prevalence Of Adrenal Incidentalomas Research Articles

Prevalence of adrenal incidentalomas in patients with neuroendocrine tumours

Prevalence of adrenal incidentalomas in patients with neuroendocrine tumours

Adrenal Incidentaloma Prevalence and Clinical Management- A Retrospective Study

This study aims to investigate the characteristics and prevalence of adrenal incidentalomas and subsequent clinical practice among patients in Armed Forces Hospital Southern Region -Saudi Arabia, 2021. An observational retrospective study was conducted in Armed Forces Hospital Southern Region -Saudi Arabia on the medical records of 383 consecutive patients. Patients with incidental adrenal tumors who underwent abdominal CT scans with intravenous contrast during the period from January 2013 and December 2021. A total of 300 patients were included in this study. However, the data were analyzed using statistical tests. The results revealed that most patients with adrenal incidentalomas were above 60 (53.3%%). The gender distribution was nearly equal, with 50.3% females and 49.7% males. Most observed tumors were unilateral (96.0%), while a small percentage was bilateral (4.0%). In terms of size, the majority were less than 1 cm (59.0%), followed by sizes greater than 4 cm (31.0%) and 1-4 cm (10.0%). Further analysis indicated that 49.3% were found to have functioning tumors, while 50.7% had non-functioning tumors. The specific types of functioning tumors included non-functioning adrenal adenoma (50.7%), pheochromocytoma (16.9%), Cushing’s syndrome (5.8%), and other functional tumor types (28.0%). Most of these patients were not referred to endocrine clinics. Adrenal incidentalomas are prevalent in the above-60 age group, with most tumors being non-functional. Further research into adrenal incidentalomas associated with diabetes and hypertension is required.

Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient

AbstractThe prevalence of adrenal incidentaloma (AI) in imaging studies, including those of the adrenal glands, is estimated to be 1–5%. Essential factors for the proper management of AI include a correct diagnosis, adequate surgical skills, appropriate perioperative management, and sound dialogue with the patient. Aside from the possibility of overdiagnosis, patients with apparent signs or symptoms attributable to adrenal hormone excess have reasonable indications for surgery. At the same time, milder patients may be candidates for active surveillance without intervention. Even individuals with nonfunctioning AI may benefit from surgery if imaging studies depict the tumor as suggestive of malignancy. However, a differential diagnosis of AI may not be easy for surgeons with little experience in seeing such patients.Furthermore, a patient without a correct diagnosis may miss the window of opportunity for a cure or incur a greater risk of developing complications, such as adrenal insufficiency or cardiovascular events during or after surgery, due to inadequate management. The clinical practice guidelines for AI from around the world may be helpful for shared decision-making; however, Japan lacks established guidelines. In this review article, we propose practical guidelines relevant to management by summarizing the evidence for five key questions that are often asked in dialog with patients with AI.

Prevalence of adrenal incidentaloma in patients performed thorax computed tomography for suspected COVID-19 infection

Aims: The primary purpose of this study is to make a retrospective evaluation of adrenal incidentaloma (AI) prevalence in patients performed thorax computed tomography (TCT), along with determining whether the diagnosed AIs were assessed functionally for adrenal gland hyperfunction and to detect the rate of hyperfunctional AI.
 Methods: The patients who applied to with the suspected COVID-19 and performed TCT between January 2020 and December 2021, were included in the present study. However, the patients who were followed-up due to a known adrenal mass and a malignant tumor were excluded.
 Results: TCT imaging, including adrenal glands, was performed on 2580 patients. The mean age for these patients was 54±16.8. However, when the patients were separated into groups in terms of adrenal pathology (AP), the mean age for the patients with and without AP was 61.4±11 and 53.8±16.9, respectively (p

Prevalence of Adrenal Incidentalomas in South-Indian Population.

Prevalence of Adrenal Incidentalomas in South-Indian Population.

Prevalence, Diagnosis and Management of Adrenal Incidentalomas

Adrenal incidentalomas (AIs) are defined as adrenal masses incidentally discovered on imaging studies performed for unrelated reasons. AIs have become a common finding in clinical practice, particularly with the widespread application of high-resolution imaging techniques. While most AIs are nonfunctioning and benign, some cases can represent a clinical concern due to the risk of malignancy or hormone hyperfunction. The prevalence of AIs varies depending on the source of data and patient selection. The diagnosis of AIs relies on a combination of radiological, biochemical, and clinical evaluation to determine the functional status of the tumor and the potential for malignancy. The management of AIs remains a subject of controversy, with guidelines providing conflicting recommendations on the indications for surgical intervention and follow-up. Most AIs do not require surgical intervention, but appropriate follow-up is essential to detect any potential growth or functional changes. In cases where surgery is indicated, laparoscopic adrenalectomy is the gold standard, with open adrenalectomy reserved for masses highly suspicious for adrenal cortical carcinoma. A multidisciplinary approach involving endocrinologists, radiologists, and surgeons is crucial for optimal management of AIs.

Abstract 108

Background and Objective: A comprehensive review in 2003 reported adrenal incidentaloma (AI) prevalence of 0.6 (0.35-varies from 0.6 to 1.5% on computed tomography (CT)-based studies. However, a few subsequent studies reported higher (4.4-7.3%) prevalence, which is often cited as the prevalence of AI and is attributed to a greater detection rate with modern imaging. Hence, we performed a systematic review and meta-analysis to evaluate the prevalence of AI. Methods: The Pubmed database was searched for literature published between the years 2000 and 2021, without language restriction and selection of articles was performed as per the PRISMA guidelines. The data was analysed via meta-analysis for proportions using MedCalc Statistical Software version 19.2.6. Results: The meta-analysis included 22 studies of which 20 were retrospective. Pooled AI prevalence rates were 1.36% (95% CI: 1.33-1.39) and 2.19% (95% CI: 1.77-2.65) with I2 of 99.1% (99-99.3%) (Fig 1). The pooled (fixed effect model) AI prevalence rates were 3.89% (95% CI: 3.34-4.51) in smaller studies (n: < 1000) and 3.76% (95% CI: 3.35-4.2) in studies with selected population (screening for lung cancer, type 2 diabetes mellitus and living potential kidney donors). In larger studies (n: > 1000) including unselected population, the pooled AI prevalence rates were 1.34% (95% CI: 1.31-1.36) and 1.43% (95% CI: 1.03-1.89) with I2 of 99.5% (99.4-99.6%). Conclusions: Pooled AI prevalence in the meta-analysis is around 1.35%. Studies that are smaller or include selected population may overestimate the AI prevalence. However, larger, prospective studies are required to verify whether it is overestimation in smaller studies or underestimation in larger, retrospective studies.

Specific characteristics of metabolomics as assessed by gas chromatography-mass spectrometry in patients with adrenocortical cancer and with adrenal incidentalomas in congenital adrenal hyperplasia

Background: Prolonged episodes of uncontrolled congenital adrenal hyperplasia (CAH) have been shown to result in the occurrence of secondary adrenal neoplasms. Prevalence of adrenal incidentalomas in the patients with 21-hydroxylase deficiency ranges from 11% to 82%. As assessed by gas chromatography-mass spectrometry (GC-MS), patients with adrenocortical cancer (ACC) have increased level of steroid hormone precursors due to decreased activity of adrenal steroidogenesis enzymes, mainly that of 21-hydroxylase and 11-hydroxylase. It seems relevant to compare the specific characteristics of steroid metabolism by GC-MS in ACC patients and in patients with adrenal incidentalomas and CAH associated with 21-hydroxylase deficiency (21-OHD).
 Aim: To identify (by GC-MS) common abnormalities in steroid metabolism and differential diagnostic biomarkers in ACC patients and CAH patients with 21-OHD and adrenal masses.
 Materials and methods: The study included 41 patients with adrenal cortex neoplasms aged 18 to 65 years without clinical and laboratory signs of endogenous hypercortisolism. Twenty three (23) patients had non-metastatic ACC and 18 patients had CAH due to 21-OHD. The control group included 26 healthy blood donors aged 20 to 59 years. Urine steroid profiles were measured by GC-MS with a gas chromatograph-mass spectrometer (Shimadzu GCMS-QP2020).
 Results: In the ACC patients, there was an increase in urinary excretion of tetrahydro-11-deoxycortisol, dehydroepiandrosterone, androstenediol-17, etiocholanolone, pregnenediol, and 3,16,20-pregnenetriol (3,16,20-dP3), as well as a decrease in the 3,16,20-dP3/3,16,20-dP3 ratio, compared to the values in the patients with CAH due to 21-OHD. Compared to the healthy control, 21-hydroxylase, 11-hydroxylase, 5-reductase and 11-hydroxysteroid-dehydrogenase (11-HSDH) type 2 activities were lower. Compared to the ACC patients, those with CAH due to 21-OHD had higher urinary excretion of 11-oxo-pregnanetriol (11-oxo-P3) and 21-deoxy-tetrahydrocortisol and lower 5-THF+5-THF+THE)/11-oxo-P3 ratio of 9.0, determination of 11-oxo-dP3, signs higher 5-reductase activity and lower 11-HSDH type 1 activity. The ACC patients and the patients with CAH due to 21-OHD had common abnormalities of steroid metabolism, such as lower activities of 21-hydroxylase, 3-hydroxysteroid-dehydrogenase and 11-hydroxylase, and no differences in urinary excretion of a number of ACC biomarkers (androgens, pregnanediol, and 5-ene-pregnenes).
 Conclusion: The assessment of urinary excretion of androgens, progestagens, and glucocorticoids by GC-MS made it possible to identify common abnormalities in steroid metabolism in the patients with ACC and CAH due to 21-OHD, which confirms the role of disordered steroidogenesis in the formation of adrenocortical tumors.

A multidisciplinary approach to the management of adrenal incidentaloma

ABSTRACT Introduction: An adrenal incidentaloma (AI) is an adrenal neoplasm incidentally discovered during an imaging unrelated to suspected adrenal disease. The aim of the present review is to offer practical guidance on the multidisciplinary approach of AIs. Areas covered: The prevalence of AI is high in the aging population (up to 5–8%); however, hormonally active or malignant conditions are rare. After the discovery of an AI, it is suggested to assess in parallel if the mass is potentially malignant and functionally active. The answer to the former question is mainly based on medical history (extra-adrenal malignancies, new-onset of signs or symptoms) and imaging (conventional radiology and/or nuclear medicine). The answer to the latter question is a complete endocrine evaluation of both cortical (glucocorticoids, mineralocorticoids) and medullary (catecholamines) secretion. Expert opinion: A multidisciplinary discussion is suggested for patients with adrenal disease, after the exclusion of nonfunctioning benign cortical adenoma, in order to plan a close and tailored follow-up for the suspected malignant or functioning forms. Surgery is advised for patients with malignant disease (adrenocortical cancer) or with clinically relevant secreting neoplasm (primary aldosteronism, Cushing’s syndrome, and pheochromocytoma).

Bilateral Adrenal Incidentalomas, Uncommon Presentation and Very Rare Pathology

Background: Adrenal incidentaloma is an adrenal mass larger than 1cm accidentally discovered by radiological examination. The incidentalomas should be evaluated for malignancy and functionality. The prevalence of adrenal incidentaloma is 4–10%,1 and around 10–15% of incidentally discovered adrenal masses can be bilateral.2 We present a patient with bilateral adrenal masses due to primary adrenal lymphoma. Clinical Case: 74-year-old gentleman, with past medical history of type-2 Diabetes mellitus, hypertension, presented to our hospital with 2 months history of right-sided flank pain, 20 kg weight loss, loss of appetite and dizziness. Otherwise, no fever, night sweats, bleeding per rectum or urinary symptoms. On physical examination, vital signs were within normal, no remarkable findings other than tenderness over the right flank. Complete blood count and chemistry panel were within normal. Abdominal CT scan was done for evaluation of the abdominal pain which showed two large masses replacing the adrenal glands measure about 10cm in diameter with patchy areas of enhancement. Adrenal insufficiency was suspected based on the symptoms and the CT scan findings. Short syncatin test (high-dose test 250mcg) was done, which showed a cortisol baseline 152nmol/L, 30 minutes 168nmol/L, and 60 minutes 169nmol/L. This was suggestive of adrenal insufficiency, so he was started on hydrocortisone. Screening for pheochromocytoma was done as the patient developed uncontrolled BP readings prior to a scheduled adrenal biopsy. 24-hour urine metanephrines and normetanephrine were negative. CT-guided adrenal mass biopsy showed findings suggestive of large B-cell lymphoma. FDG PET-CT scan showed huge bilateral intense FDG uptake in the adrenal glands with no extra-abdominal manifestations noted. He was started on R-CHOP chemotherapy and after 4cycles, a PET scan showed a significant decrease in the size of previous adrenal masses. Conclusion: Bilateral adrenal incidentaloma should be evaluated the same as unilateral adrenal mass. Although adrenal involvement is common in non-Hodgkin lymphoma, primary adrenal lymphoma is extremely uncommon.

Atypical Adrenaliemmas

Introduction: Adrenal Incidentalomas (AI) are increasingly found with recent proliferation in imaging techniques. The precise prevalence of AI is not well established but estimated to be about 5%. Such findings require thorough work and follow up plans to assess for hormonal functionality and differentiate between benign or a malignant entity. Adrenocortical carcinoma (AC), schwannoma (SCH), ganglioneuroma (GN), myelolipoma (ML), neuroblastoma (NB), and ganglioneuroblastoma (GNB) are a rare presentation of AIs. In this case series, we present 2 cases of uncommon AIs. Cases Series: Case 1: A 55-year-old man presented to the hospital with episodic dizziness, nausea, vomiting, and diaphoresis. His physical examination and blood workup were unremarkable. He takes multiple antihypertensive medications at home. CT abdomen revealed an incidental 5 cm mass adjacent to the left adrenal gland which was confirmed to be of adrenal origin on MRI. The hormonal workup was negative. and patient. Laparoscopic left adrenalectomy was performed. Histopathological diagnosis pointed to a benign nerve sheath tumor. Tumor cells stained positive for S-100 and negative for CD34 and epithelial membrane antigen. The morphologic features and immunohistochemical profile consistent with adrenal SCH diagnoses, confirmed by two histopathologists. Postoperatively, Blood pressure improved, and the patient has no evidence of recurrence on subsequent follow-ups. Case 2: A 38-year-old female presented to the hospital with severe right groin pain. During the workup, a CT abdomen revealed a homogeneous, lobulated, minimally enhanced, 5.8 cm right adrenal mass with no calcifications. The hormonal workup was negative. FDG-PET scan showed low uptake in the right adrenal mass. Adrenalectomy was performed and histological examination revealed Schwan cells and neurites with occasional ganglion cells compatible with benign GN. Discussion: SCHs originate from Schwann cells in peripheral nerve sheaths. Adrenal SCHs are rare, they represent about 0.5% of all SCHs. Surgical resection is the initial management as imagings are non-diagnostic and appearance does not distinguish benign from malignant lesions. Adrenal GNs originate from neural crest cells in the adrenal medulla and represents between 20–30% of all GNs. They may be primary or evolve from differentiating NB. The majority of them are sporadic. GNs are typically benign and asymptomatic. However, larger GNs are associated with an increased risk of malignancy, a 33% risk for 5 cm compared to 92% for 6 cm. Surgical resection is necessary, especially for larger masses. Conclusion: Besides the common adrenal incidentalomas and their proper work and follow up plans, a clinician should consider atypical adrenal tumors with unusual presentation. Surgical treatment and histological examination are essential for an accurate diagnosis.

Інсиденталома надниркової залози: що це таке? Частина 1

Огляд літератури та власні роздуми автора присвячені питанням виявлення різних форм патології, які, будучи часто доброякісними, могли б існувати тривалий час, якщо не все життя. Автором пропонується визначення терміна. Інсиденталома надниркової залози— це збірна робоча категорія (група), що містить різні форми патології надниркової залози, переважно неопластичні, доброякісні або злоякісні, з ознаками гормональної активності або без них, а також утворення запального, інфекційного, паразитарного походження, наслідки травм, аномалії розвитку, які випадково виявляються при обстеженні хворих із приводу позанаднирникових захворювань. Розглядаються епідеміологічні аспекти інсиденталом надниркової залози. В основному це пухлини коркової або мозкової речовини надниркових залоз, пухлиноподібні утворення (кіста, запальна пухлина, гематома). Інсиденталоми наднирників випадково виявляються при обстеженні осіб із захворюваннями шлунково-кишкового тракту, заочеревинного простору, нирок, хребта, грудної клітки, малого таза. Іншим джерелом виявлення інсиденталом наднирників є системні дані автопсії та рідко— операції на органах черевної порожнини. Поширеність інсиденталом наднирників досягає 2–6%. Найбільш об’єктивні дані можуть бути отримані за матеріалами автопсії. Частота прижиттєво виявлених інсиденталом надниркових залоз залежить від типу використовуваних візуалізуючих методик дослідження (ультразвукової, комп’ютерної томографії, магнітно-резонансної томографії), віку, характеру обстежуваних контингентів осіб, наявності супутніх захворювань (артеріальна гіпертензія, цукровий діабет та ін.), кваліфікації дослідника. Нещодавно опубліковані клінічні настанови, які пропонують діагностичний та терапевтичний алгоритм, що може допомогти в клінічній практиці, однак низка аспектів цієї проблеми все ще залишаються дискусійними і потребують подальших досліджень.

Demographic and Clinicopthologic Properties of Patients Operated for Adrenal Masses

The prevalence of adrenal incidentaloma is nearly 4 to 10% and increases with age. Most adrenal masses are nonfunctioning adrenocortical adenomas and found as an adrenal incidentaloma in 80% of cases, but also be conditions requiring therapeutic intervention. We presented our patients with adrenal masses and their management.

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients\u2019 stratification by body mass index and age

BackgroundThe escalating prevalence of adrenal incidentaloma (AI) has been associated with the improvement of radiologic techniques and widespread imaging in aging population. It is currently unclear whether patients with obesity more likely develop AI and the current rise in the prevalence of AI could be at least partly associated with the respective rise in obesity. We compared the prevalence and characteristics of non-functional (NF) and autonomous cortisol secreting (ACS) adrenal incidentalomas (AIs) after the study population was stratified by different body mass indexes (BMI) and age groups.MethodsRetrospective cross-sectional study comprising of 432 patients (40.6% male, 59.4% female) with NFAI (N = 290) and ACS (N = 142), of median age 63.4 (54.0–71.6) years and median BMI 28.6 (25.5–31.7) kg/m2. The data collection contained 11.132 points including demographic, anthropometric, radiologic, hormonal and metabolic parameters.ResultsWe observed 68–87% higher prevalence of AI across different age groups in NFAI and ACS in obese/overweight compared to normal weight subjects. Patients with ACS were older (P = 0.008), with higher basal cortisol (P < 0.001), lower basal DHEAS (P = 0.001), lower suppression DHEAS (P = 0.027) and higher aldosterone (P = 0.039). AIs with ACS were larger than NFAI (P < 0.001). Interestingly, ACS group had lower body mass (P = 0.023) and did not differ in BMI, blood pressure, heart rate, lipid profile, fasting glucose and presence of diabetes mellitus type 2 when compared to NFAI., By contrast to the similarity of metabolic profiles in ACS and NFAI, some components of adverse metabolic traits were rather associated with higher BMI and older age, in particular in NFAI.ConclusionThe prevalence of NFAI and ACS were significantly higher in overweight/obese subgroup across the age distribution. Stratification by age and BMI displayed significant differences in some metabolic traits, in particular in NFAI.

Adrenal incidentaloma: management of patients with functionally autonomous cortisol synthesis

Over recent decades due to improved visualization (ultrasound, computer tomography and magnetic resonance imaging) prevalence of adrenal incidentaloma has increased. The term «adrenal incidentaloma» is generic and includes a group of tumors of various morphology and over 1 cm in diameter accidentally discovered during radiologic investigation. The found tumor can be hormonally inactive or actively releasing different hormones, malignant or benign, and originating from different adrenal zones or having non-specific organ origin. Based on the frequency of revealing and clinical significance the most noteworthy is functionally autonomous cortisol synthesis. It means changes of hypothalamic pituitary adrenal axis without classic clinically prominent signs of cortisol excess such as proximal myopathy, stretch marks, body fat redistribution and other metabolic changes related to cortisol. Currently a large number of recommendations on the management and tactics of treatment of adrenal incidentaloma can be found in the literature. Based on the analysis of these guidelines the conclusions were made about the diagnostic errors and incorrect approaches to the choice of treatment of such patients. Recently a lot of studies have been directed to the early detection of carbohydrate and lipid metabolism disorders, relation with obesity and type 2 diabetes mellitus, arterial hypertension and osteoporosis for preserved quality of life of such patients. Influence of hypercorticism is considered to worsen the course of these conditions but at the moment no effect of adrenalectomy on mortality and life duration was confirmed.

SAT-365 Prevalence and Clinical Features of Adrenal Incidentalomas: A Prospective Study in an Unselected Population

Context. The widespread use of cross-sectional imaging in medical practice has increased detection of adrenal tumors, which are most frequently unexpected prior to their discovery (adrenal incidentalomas). Most adrenal incidentalomas (AI) are benign and frequently cause low-grade cortisol excess that may portend adverse clinical consequences. However, this association is subject to confounding by indication since more diagnostic tests are done in diseased patients. Objective. To assess prospectively the prevalence of AI in an unselected adult population performing abdominal CT in our catchment area, and to evaluate the demographic, laboratory and clinical features of AI patients. Design and setting. Monocentric, prospective study. Patients. A consecutive series of 601 unselected patients undergoing abdominal CT as part of their management. Patients with any known adrenal disorder or malignancy were excluded. Results. Of the 601 patients, aged 63.5 ± 14.4 years, 55.4% had hypertension, 15.1% diabetes, 16.8% dyslipidemia and 16% previous CV events. These characteristics are overall comparable to the background general population. We found serendipitously 44 adrenal tumors (7.3%), 43 with radiological features of benign cortical adenoma (density <10 HU) and 1 with indeterminate features, which was a pheochromocytoma. Mass size ranged between 1-5 cm (median 2 cm) and tumors were bilateral in 29.5%. Patients with AI compared to patients without were more frequently suffering from diabetes (31.8% vs 14.2%; p=0.004), showing higher BMI (27.6 ± 6.2 vs. 25.6 ± 4.8; p=0.009) and larger waist (101.2 ± 13.9 cm vs. 95.3 ± 13.9 cm; p=0.007). No differences were found in frequency of hypertension, dyslipidemia or history of CV events. Forty patients underwent a 1-mg overnight dexamethasone test (DST) and 20 (50%) did not suppress cortisol below 1.8 μg/dL (4 had post-DST cortisol >5.0 μg/dL). Post-DST cortisol levels were not different between diabetic and non-diabetic AI patients (3.5 ± 4.0 µg/dL vs. 2.4 ± 2.5 µg/dL). In multivariate analysis, diabetes was significantly associated with AI (p=0.003). Conclusions. We confirm in a prospective study the high prevalence of previously unsuspected adrenal tumors, most of which are benign adenomas. Moreover, we found a significant association between adrenal incidentalomas and diabetes. Since our patients were recruited at the radiology department, this finding is not confounded by selection bias.

Laparoscopic adrenalectomy for ganglioneuroma presenting as an adrenal incidentaloma.

Adrenal incidentaloma (AI) has now become a common finding in clinical practice with advances in abdominal imaging. The prevalence of AI as reported in the literature is 0.2%–3%. Ganglioneuroma (GN) is often a benign non-functioning adrenal tumour, which has been rarely reported as AI in literature. Confirmed diagnosis of GN can only be done by histopathological examination. GNs are often asymptomatic even if they are large, and adrenalectomy is treatment for GN, with good prognosis after surgical removal. Here, we report a patient with an incidental adrenal mass that was managed laparoscopically and diagnosed as an adrenal GN on histopathology.

Characteristics of adrenal incidentalomas in a New Zealand centre.

Management of adrenal incidentalomas (AI) is becoming more conservative, based on international data showing a low incidence of functional or malignant lesions. The clinical characteristics of AI in New Zealand are unknown. Therefore, whether the AI guidelines apply to the New Zealand population is also unknown. To investigate the clinical characteristics of patients with AI presenting to a tertiary-care centre in New Zealand. This study prospectively evaluated consecutive patients aged 18 or older with AI, 1 cm or larger, diagnosed in Canterbury, New Zealand. A standardised nurse-led dedicated AI clinic was used, including clinical assessment, hormonal evaluation and imaging. From January 2010 to April 2016, 306 patients were referred to the AI clinic, 228 met the inclusion criteria. Most of those excluded were not true AI, due to imaging performed for known or suspected non-adrenal malignancy. The most common reason for imaging was abdominal pain (46%). Most cases were benign (96.5%) and 88.6% of all cases were non-functional. Of the functioning tumours (26 patients), 18 had subclinical Cushing syndrome, four had late-onset congenital adrenal hyperplasia, two had phaeochromocytoma and one had primary hyperaldosteronism. Three patients had primary adrenal cancer, one of whom was secreting excess cortisol. One adrenal metastasis was diagnosed. This study found a similar prevalence of functional and malignant AI as international centres, although mild cortisol excess and primary aldosteronism may be under-represented. Therefore, the conservative approach to management of AI recommended in current guidelines is likely to be applicable to New Zealand population.

2048

OBJECTIVES/SPECIFIC AIMS: To compare methods of ascertaining prevalence for adrenal incidentalomas METHODS/STUDY POPULATION: Retrospective electronic medical record study using Looking Glass Clinical Analytics (Streamline Health, Atlanta, GA, USA) at an urban university medical center. All patients with CT or MR imaging of the abdomen between 1997 and 2014 were identified. Patients with a documented diagnosis (ICD-9 code or problem list) for any history of adrenal disease were excluded. The prevalence of adrenal incidentalomas was ascertained by 2 different detection strategies: (1) documented diagnosis of adrenal incidentaloma or (2) imaging reports containing in the same sentence “adrenal” and “nodule*,” “adenoma*,” or “mass*,” and not containing “no” and “adrenal” in the same sentence. Adrenal pathology surprise was further established in the second approach by excluding patients having previously undergone adrenal lab testing (cortisol, aldosterone, catecholamines, adrenocorticotropic hormone, renin) or having been registered in the cancer registry for any cancer excluding superficial skin cancers. RESULTS/ANTICIPATED RESULTS: In total, 194,624 individuals were identified in our initial search, from which 1056 were excluded for past adrenal disease (Table 1). Detection by the documented diagnosis method yielded 1578 cases (0.8%), compared with 13,697 cases (7.1%) by the imaging report method (Figure 1). Further restricting detection to true “Adrenal Surprise” by excluding those with any past adrenal lab testing and cancer history yielded 10,568 cases (6.1%). Validation studies for the 7.1% prevalence with 100 records revealed an adrenal incidentaloma positive predictive value (PPV) of 98%. When restricted to size ≥1 cm the PPV was 84%. DISCUSSION/SIGNIFICANCE OF IMPACT: Comparing our first strategy using documented diagnoses as criterion for incidentaloma as used in a recent paper by Lopez D (Annals of Internal Medicine 2016; 165: 533–542), we found a prevalence of 0.8% in our population similar to her 0.6%. However, when searching at the level of radiology report text, we found a prevalence ten-fold greater at 7.1%. Therefore, adrenal incidentalomas are more robustly identified by searching radiologic reports.

Sa1278 - Prevalence of Adrenal Incidentaloma in Gastric Cancer Patients

Sa1278 - Prevalence of Adrenal Incidentaloma in Gastric Cancer Patients